RVSV-ZEBOV vaccine: Difference between revisions
CSV import |
CSV import |
||
| Line 31: | Line 31: | ||
{{stub}} | {{stub}} | ||
<gallery> | |||
File:Ebola virus em.png|RVSV-ZEBOV vaccine | |||
File:2014 ebola virus epidemic in West Africa simplified.svg|RVSV-ZEBOV vaccine | |||
File:Ebola Geimpfte Kongo.png|RVSV-ZEBOV vaccine | |||
</gallery> | |||
Latest revision as of 01:01, 20 February 2025
RVSV-ZEBOV vaccine is a vaccine used to protect against Ebola virus disease. It was developed by the Public Health Agency of Canada and is now licensed to Merck & Co. The vaccine is a recombinant, replication-competent vesicular stomatitis virus-based candidate vaccine expressing a surface glycoprotein of Zaire Ebolavirus.
Development[edit]
The development of the RVSV-ZEBOV vaccine began in the early 2000s at the National Microbiology Laboratory of the Public Health Agency of Canada. The vaccine was then licensed to NewLink Genetics, which was subsequently acquired by Merck & Co.
Efficacy[edit]
The RVSV-ZEBOV vaccine has been shown to be effective in preventing Ebola virus disease in clinical trials. A trial conducted in Guinea during the 2014-2016 Ebola outbreak showed that the vaccine was highly effective.
Usage[edit]
The RVSV-ZEBOV vaccine is used in a "ring vaccination" approach, where all people who have come into contact with an Ebola patient are vaccinated to prevent the spread of the disease. It is also used to vaccinate healthcare workers who are at high risk of infection.
Side Effects[edit]
Common side effects of the RVSV-ZEBOV vaccine include headache, fatigue, muscle pain, and fever. Serious side effects are rare but can include allergic reactions.
